Description

CJC-1295 (No DAC) + Ipamorelin Blend

CJC-1295 without DAC (Mod GRF 1-29) and Ipamorelin are two complementary research peptides combined for laboratory investigations into growth hormone signaling. CJC-1295 (No DAC) is a synthetic growth hormone-releasing hormone (GHRH) analog, while Ipamorelin is a selective growth hormone secretagogue. Together they have been studied in preclinical models examining the two distinct pathways that regulate growth hormone release.

Supplied as a lyophilized research blend for controlled laboratory investigations.

For laboratory research use only. Not for human or animal consumption.

OVERVIEW

This blend pairs a GHRH analog with a growth hormone secretagogue to study their combined and complementary mechanisms.

CJC-1295 (No DAC), also known as Modified GRF 1-29, is a shortened analog of growth hormone-releasing hormone. It has been investigated in laboratory models for its interaction with GHRH receptors and its influence on growth hormone-releasing signaling. The “No DAC” form lacks the Drug Affinity Complex, resulting in a shorter half-life and a more pulsatile release profile in research models compared to CJC-1295 with DAC.

Ipamorelin is a selective pentapeptide growth hormone secretagogue that acts on the ghrelin/growth hormone secretagogue receptor (GHS-R). Laboratory research has examined its growth hormone-releasing activity and its selectivity relative to other secretagogues.

These findings remain investigational and do not establish the blend as an approved treatment or therapeutic product.

PRODUCT SPECIFICATIONS

(Verify all values against the applicable batch Certificate of Analysis.)

Compounds: CJC-1295 (No DAC / Mod GRF 1-29) + Ipamorelin
Quantity: (confirm per-peptide amounts against batch CoA — e.g. __ mg CJC-1295 + __ mg Ipamorelin)
Form: Lyophilized powder
Storage: 2–8°C recommended; protect from light and moisture
Purity: Refer to the current batch Certificate of Analysis

CJC-1295 (No DAC): Sequence corresponds to Modified GRF 1-29; CAS and molecular weight should be confirmed against the batch CoA.
Ipamorelin: Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂; CAS 170851-70-4; confirm against batch CoA.

RESEARCH APPLICATIONS

• Growth hormone signaling research
• GHRH receptor pathway studies
• Ghrelin / GHS-R receptor investigations
• Growth hormone pulsatility models
• Pituitary cell-response research
• Secretagogue selectivity studies
• Comparative peptide-signaling research
• Endocrine pathway models

RESEARCH BACKGROUND

CJC-1295 (No DAC) and Ipamorelin are frequently studied together because they act on two separate pathways that regulate growth hormone release. CJC-1295 (No DAC) mimics GHRH and has been investigated for its interaction with GHRH receptors, while Ipamorelin stimulates the growth hormone secretagogue receptor, the same receptor targeted by the hormone ghrelin.

In laboratory studies, this combination has been examined to understand how GHRH-analog and secretagogue signaling interact in cellular and animal models. Research has reported effects on growth hormone-releasing activity, signaling selectivity, and release patterns.

Results from cell and animal models should not be interpreted as evidence of safety, efficacy, dosage, or approved therapeutic use in humans.

RESEARCH USE ONLY

This product is intended strictly for qualified laboratory research.

Not for human consumption. Not for veterinary use. Not for injection. Not for therapeutic or diagnostic applications. Not intended to diagnose, treat, cure, or prevent any disease or medical condition.

Use is limited to qualified professionals conducting controlled laboratory investigations in accordance with applicable institutional, regulatory, and safety requirements.

Certificate of Analysis available for applicable product batches.